Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 56%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics Inc is experiencing robust growth in its Filspari prescribing, with a notable increase in new patient start forms by 37% quarter-over-quarter in the fourth quarter of 2024. The company is positioned for significant market expansion with its ongoing regulatory initiatives, including a supplemental new drug application for Filspari targeting focal segmental glomerulosclerosis (FSGS), projected to contribute to a sizable market opportunity of approximately $521 million by 2030. Additionally, improvements in gross-to-net discounts, alongside favorable physician insights suggesting rapid uptake in FSGS for Filspari, indicate a strong potential for continued revenue momentum and overall positive market reception.

Bears say

The financial outlook for Travere Therapeutics Inc appears negative due to significant commercial risks associated with its pipeline product, Filspari. The company's survey indicates that a majority of IgAN patients fall below the crucial threshold for the growth driver, potentially limiting Filspari's market penetration. Furthermore, increasing competition in the market, along with the possibility of generic entry and the presence of drugs with superior efficacy or safety profiles, raises concerns about Travere's ability to meet revenue expectations in both IgAN and FSGS indications.

Travere Therapeutics (TVTX) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 56% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 16 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.